Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Diabetes & metabolic syndrome

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.DSX.2019.05.034PMID 31405699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid

  2020cited by this paper
• Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

  2018cited by this paper
• Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα.

  2018cited by this paper
• Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

  2018cited by this paper
• Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome

  2018cited by this paper
• Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

  2017cited by this paper
• Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

  2013cited by this paper
• Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants

  2012cited by this paper
• Effects of combination lipid therapy in type 2 diabetes mellitus.

  2010cited by this paper
• Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease.

  2009cited by this paper
• Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.

  2007cited by this paper
• Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors

  2007cited by this paper
• Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

  2006cited by this paper
• The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha.

  2004cited by this paper
• Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.

  2004cited by this paper
• The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor α

  2004cited by this paper
• Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

  1999cited by this paper
• Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.

  1999cited by this paper
• Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

  1990cited by this paper

• Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia

  2025cites this paper
• Statin alternatives for the treatment of hypercholesterolemia - a safety evaluation

  2024cites this paper
• The dawn of a new era of targeted lipid-lowering therapies.

  2022cites this paper
• Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid

  2020cites this paper
• Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes

  2020cites this paper